- Home
- CELC vs ATAI Comparison
CELC vs ATAI Comparison
Compare CELC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- ATAI
- Stock Information
- Founded
- CELC 2011
- ATAI 2018
- Country
- CELC United States
- ATAI Germany
- Employees
- CELC N/A
- ATAI N/A
- Industry
- CELC Medical Specialities
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CELC Health Care
- ATAI Health Care
- Exchange
- CELC Nasdaq
- ATAI Nasdaq
- Market Cap
- CELC 327.3M
- ATAI 282.6M
- IPO Year
- CELC 2017
- ATAI 2021
- Fundamental
- Price
- CELC $11.62
- ATAI $2.49
- Analyst Decision
- CELC Strong Buy
- ATAI Strong Buy
- Analyst Count
- CELC 5
- ATAI 3
- Target Price
- CELC $30.80
- ATAI $10.50
- AVG Volume (30 Days)
- CELC 148.5K
- ATAI 2.4M
- Earning Date
- CELC 05-14-2025
- ATAI 05-14-2025
- Dividend Yield
- CELC N/A
- ATAI N/A
- EPS Growth
- CELC N/A
- ATAI N/A
- EPS
- CELC N/A
- ATAI N/A
- Revenue
- CELC N/A
- ATAI $1,863,000.00
- Revenue This Year
- CELC N/A
- ATAI $242.21
- Revenue Next Year
- CELC N/A
- ATAI N/A
- P/E Ratio
- CELC N/A
- ATAI N/A
- Revenue Growth
- CELC N/A
- ATAI 572.56
- 52 Week Low
- CELC $7.58
- ATAI $1.03
- 52 Week High
- CELC $19.77
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- CELC 64.24
- ATAI 80.34
- Support Level
- CELC $10.50
- ATAI $2.18
- Resistance Level
- CELC $10.88
- ATAI $2.38
- Average True Range (ATR)
- CELC 0.62
- ATAI 0.20
- MACD
- CELC 0.05
- ATAI 0.07
- Stochastic Oscillator
- CELC 90.17
- ATAI 88.14
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.